Abstract
Syndecan-1 (CD138) is a transmembrane heparin sulfate proteoglycan expressed on distinct stages of differentiation of
Syndecan-1 (CD138) is a transmembrane heparin sulfate proteoglycan expressed on distinct stages of differentiation of
E Ruoslahti and Y Yamaguchi, “Proteoglycans as modular of growth factor activities,” Cell, vol. 64, pp. 867–869, 1991.
View at: Google ScholarM Bernfield, R Kokenyesi, M Kato et al., “Biology of the sydecans: a family of four transmembrane heparan sulphate proteoglycans,” Annual Review of Cell Biology, vol. 8, pp. 365–393, 1993.
View at: Google ScholarK Elenius and M Jalkanen, “Function of the syndecans: a family of cell surface proteoglycans,” Journal of Cell Science, vol. 107, no. 11, pp. 2975–2982, 1994.
View at: Google ScholarR D Sanderson, P Lalor, and M Bernfield, “B lymphocytes express and lose syndecan at specific stages of differentiation,” Cell Regulation, vol. 1, no. 1, pp. 27–35, 1989.
View at: Google ScholarM V Dhodapkar, T Kelly, A Theus, A B Athota, B Barlogie, and R D Sanderson, “Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma,” British Journal of Haematology, vol. 99, no. 2, pp. 368–371, 1997.
View at: Google ScholarM V Dhodapkar, E Abe, A Theus et al., “Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation,” Blood, vol. 91, no. 8, pp. 2679–2688, 1998.
View at: Google ScholarR C Ridley, H Xiao, H Hata, J Woodlif, J Epstein, and R D Sanderson, “Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen,” Blood, vol. 81, no. 3, pp. 767–774, 1993.
View at: Google ScholarC Seidel, A Sundan, M Hjorth et al., “Serum syndecan-1: a new independent prognostic marker in multiple myeloma,” Blood, vol. 95, no. 2, pp. 388–392, 2000.
View at: Google ScholarA Sebestyen, L Berczi, R Mihalik, S Paku, A Matolcsy, and L Kopper, “Syndecan-1 (CD138) expression in human non-Hodgkin lymphomas,” British Journal of Haematology, vol. 104, no. 2, pp. 412–419, 1999.
View at: Google ScholarT E Witzig, T Kimlinger, M Stenson, and T Therneau, “Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia,” Leukemia and Lymphoma, vol. 31, no. 1-2, pp. 167–175, 1998.
View at: Google ScholarB D Cheson, J M Bennett, M Grever et al., “National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment,” Blood, vol. 87, no. 12, pp. 4990–4997, 1996.
View at: Google ScholarF Bertolini, M Paolucci, F Peccatori et al., “Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma,” British Journal of Haematology, vol. 106, no. 2, pp. 504–509, 1999.
View at: Google ScholarC Basilico and D Moscatelli, “The FGF family of growth factors and oncogenes,” Advances in Cancer Research, vol. 59, pp. 115–165, 1992.
View at: Google ScholarA Bikfalvi and Z C Han, “Angiogenic factors are hematopoietic growth factors and vice versa,” Leukemia, vol. 8, no. 3, pp. 523–529, 1994.
View at: Google ScholarA Konig, T Menzel, S Lynen et al., “Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis,” Leukemia, vol. 11, no. 2, pp. 258–265, 1997.
View at: Google ScholarO Bairey, Y Zimara, M Shaklai, and E Rabizadeh, “Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia,” British Journal of Haematology, vol. 113, no. 2, pp. 400–406, 2001.
View at: Google ScholarS Duensing and J Atzpodien, “Increased intracellular and plasma levels of basic fibroblast growth factor in B-cell chronic lymphocytic leukemia,” Blood, vol. 85, no. 7, pp. 1978–1979, 1995.
View at: Google ScholarI Christiansen, C Gidlof, A Wallgren, B Simonsson, and T H Tottermann, “Serum levels of soluble intercellular adhesion molecule 1 are increased in chronic B-lymphocytic leukemia and correlate with clinical stage and prognostic markers,” Blood, vol. 84, no. 9, pp. 3010–3016, 1994.
View at: Google ScholarS Molica, A Vacca, D Ribatti et al., “Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia,” Blood, vol. 100, no. 9, pp. 3344–3351, 2002.
View at: Google ScholarS Molica, G Vitelli, D Levato, A Ricciotti, and G Digiesi, “Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia,” British Journal of Cancer, vol. 86, no. 1, pp. 31–35, 2002.
View at: Google ScholarA Aguayo, H Kantarjian, T Manshouri et al., “Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes,” Blood, vol. 96, no. 6, pp. 2240–2245, 2000.
View at: Google ScholarH Chen, A T Treeweeke, D C West et al., “In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells,” Blood, vol. 96, no. 9, pp. 3181–3187, 2000.
View at: Google ScholarA R Kini, N E Kay, and L C Peterson, “Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia,” Leukemia, vol. 14, no. 8, pp. 1414–1418, 2000.
View at: Google ScholarS Molica, G Vitelli, D Levato, G M Gandolfo, and V Liso, “Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia,” British Journal of Haematology, vol. 107, no. 3, pp. 605–610, 1999.
View at: Google ScholarM O'Reilly, T Boehm, Y Shing et al., “Endostatin: an endogenous inhibitor of angiogenesis and tumor growth,” Cell, vol. 88, no. 2, pp. 277–285, 1997.
View at: Google ScholarA L Feldman, H Pak, J C Yang, H R Jr Alexander, and S K Libutti, “Serum endostatin levels are elevated in patients with soft tissue sarcoma,” Cancer, vol. 91, no. 8, pp. 1525–1529, 2001.
View at: Google ScholarA L Feldman, L Tamarkin, G F Paciotti et al., “Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer,” Clinical Cancer Research, vol. 6, no. 12, pp. 4628–4634, 2000.
View at: Google ScholarM Yamagata, Y Shiratori, Y Dan et al., “Serum endostatin levels in patients with hepatocellular carcinoma,” Annals of Oncology, vol. 11, no. 6, pp. 761–762, 2000.
View at: Google ScholarJ Góra-Tybor, J Z Błoński, and T Robak, “Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia,” Mediators of Inflammation, vol. 12, no. 3, pp. 167–171, 2003.
View at: Google ScholarR Lai, E Estey, Y Shen et al., “Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome,” Cancer, vol. 94, no. 1, pp. 14–17, 2002.
View at: Google Scholar